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Background: The resistance of endometriotic tissue to progesterone can be explained by alterations in the
distribution of progesterone receptor (PR) and estrogen receptor (ER) isoforms. The aims of this study were to
examine the expressions of PR-A, PR-B, ERα and ERβ in endometrioma and assess whether these expressions are
affected by dienogest or leuprolide acetate (LA) treatment.
Methods: We enrolled 60 females, including 43 patients with endometriosis (14 who received no medical
treatment, 13 who received dienogest and 16 who received LA before undergoing laparoscopic surgery) and 17
patients with leiomyoma. The expression levels of PR and ER isoforms in eutopic and ectopic endometrium were
assayed with quantitative real-time PCR, and confirmed with immunohistochemistry.
Results: A decreased PR-B/PR-A ratio and an increased ERβ/ERα ratio were demonstrated in ectopic endometrium
derived from females with endometriosis compared with the ratios observed in eutopic endometrium obtained
from females without endometriosis. Although LA treatment did not affect the PR-B/PR-A and ERβ/ERα ratios,
dienogest treatment increased the PR-B/PR-A ratio and decreased the ERβ/ERα ratio in patients with
endometriomas.
Conclusions: Dienogest may improve progesterone resistance in endometriotic tissue by increasing the relative
expressions of PR-B and PR-A, and decreasing the relative expressions of ERβ and ERα.
Keywords: Dienogest, Progesterone receptor isoforms, Estrogen receptor isoforms, Ovarian endometriosis,
Progesterone resistanceBackground
Endometriosis is an estrogen-dependent inflammatory dis-
ease that affects 6-10% of females of reproductive age [1]. It
is characterized by the presence of endometrium-like tissue
outside the uterine cavity, primarily on the ovaries, and
represents one of the most common causes of chronic pelvic
pain, dysmenorrhea and infertility [2]. The main aims of
treatment are to alleviate pain and other symptoms, reduce
the size of the endometriotic lesions and improve the quality
of life of affected individuals. Nonsteroidal anti-inflammatory
drugs are frequently used by patients with endometriosis in* Correspondence: gyn074@poh.osaka-med.ac.jp
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reproduction in any medium, provided the oran attempt to relieve pelvic pain, although clinical trial evi-
dence to support the efficacy of these agents in endometrio-
tic patients is lacking [3]. Gonadotropin-releasing hormone
(GnRH) agonists are an established therapy for endometri-
osis. Although GnRH agonists provide effective pain relief
and reduce the progression of endometriotic implants [4],
the hypoestrogenic state they induce is associated with nega-
tive effects such as accelerated bone mineral density loss, hot
flashes and vaginal dryness [5]. Oral contraceptives (OCs)
are widely used to treat the symptoms of endometriosis, al-
though they are not approved for this indication in the ma-
jority of countries due to the lack of supportive trial evidence
[6]. Progestins have long been used for the treatment of
endometriosis to relieve pain by suppressing ovarian estro-
gen biosynthesis, in turn, suppressing growth andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be relatively short-term [8], and approximately 9% of females
with endometriosis simply do not respond to progestin ther-
apy due to unknown reasons [9]. In fact, a general tendency
for relative progesterone resistance within the eutopic and
ectopic endometrium of females with endometriosis is well-
documented [1,10].
Recently, two major progesterone receptor (PR) iso-
forms were identified, namely PR-A and PR-B (11). PR-A
is a 94-kDa protein, whereas PR-B is a 114-kDa protein
that contains an additional NH2-terminal stretch of ap-
proximately 165 amino acids containing a region encoding
a transactivation function. These isoforms may arise as a
result of either initiation of translation from alternative
sites in the same messenger RNA (mRNA) [11] or by tran-
scription from alternative promoters [12]. Although the
exact functions of each of these isoforms remain unclear,
there is increasing evidence that they are functionally dif-
ferent [12,13]. PR-B tends to be a stronger activator of
progesterone target genes, whereas PR-A has been shown
to act as a dominant repressor of PR-B [14,15].
Endometriosis is associated with a reduced response to
progesterone in both eutopic and ectopic endometrium.
According to recent reports, the resistance of endome-
triotic tissue to progesterone, evident in both laboratory
and clinical observations, can be explained by alterations
in the distribution of ER and PR isoforms and dysregula-
tion of progesterone target genes [10,16-18]. Because the
effects of progesterone on target genes are conferred pri-
marily by PR-B in the endometrium [19], the presence of
the inhibitor isoform-A and the absence of the stimula-
tory isoform-B provide a possible explanation for pro-
gesterone resistance in endometriotic implants. In fact, a
decreased PR-B/PR-A ratio has been demonstrated in
ectopic tissue [20,21], and recent reports suggest that
the tendency toward progesterone resistance in patients
with endometriosis is likely the result of the promotion
of hypermethylation of PR-B, which renders PR-B either
silenced or downregulated [21]. Moreover, a number of
investigators have reported markedly elevated levels of
ERβ and lower levels of ERα in human endometriotic
tissues and primary stromal cells compared with that
observed in eutopic endometrial tissues and cells
[16,22,23]. ERβ, acting as an ERα suppressor, might con-
tribute to the decreased PR levels and progesterone re-
sistance observed in patients with endometriosis [24].
Dienogest (17a-cyanomethyl-17b-hydroxyestra-4,9-dien-
3-one) is an oral progestin that has been systematically
investigated for the treatment of endometriosis in dose-
ranging [25], placebo-controlled [26,27], active comparator-
controlled [28,29] and long-term trials [30] conducted in
Europe and Japan. The main anti-endometriotic effect of
dienogest has been suggested to be attributable to central
inhibition of ovulation. Furthermore, direct antiproliferativeeffects of dienogest have been demonstrated in human
eutopic endometrial stromal cells [31]. Recent studies dem-
onstrate that dienogest inhibits the proliferation of endome-
triotic stromal cells [32], prostaglandin E2 production and
the aromatase mRNA expression of the endometrial epithe-
lial cell line [33]. However, there is no evidence regarding
whether dienogest improves progesterone resistance in
patients with endometriosis. In the present study, therefore,
we examined the effects of dienogest on alterations in the
ratios of PR-B to PR-A and ERβ to ERα in ectopic endo-
metrial tissue obtained from endometriotic females.
Methods
Patients and tissue collection
Sixty patients treated between January 2002 and July
2010 were included in this study. All patients were
under treatment at the department of obstetrics and
gynecology of Osaka Medical College. This was a retro-
spective cross-sectional case-controlled study of human
tissue samples approved by the Institutional Review
Board of Osaka Medical College. Written informed con-
sent was obtained from all patients participating in the
study.
The inclusion criteria were: older than 20 years age of
and no more than 50 years of age at the time of the sur-
gical procedure, the presence of regular menstrual cycles
(24–35 days of interval) with the exception of those trea-
ted with leuprolide acetate (Leuplin; Takeda pharma-
ceutical, Osaka, Japan) for endometriosis, the absence of
any evidence of past or recent pelvic inflammatory dis-
ease and no history of any hormonal treatment for at
least 12 months at baseline. Trans-vaginal ultrasonog-
raphy was performed for all patients, and showed mainly
hypoechoic cystic masses in the ovaries, and the pres-
ence of ovarian endometriomas were confirmed before
surgery by magnetic resonance imaging (MRI), which
showed high-intensity areas on both T1- and T2-
weighted images. The serum level of CA125 was also
measured before surgery using automated assays on a
Roche Modular E170 instrument (Roche, Vilvoorde, Bel-
gium) at the central laboratories of Osaka Medical Col-
lege. Tissue specimens were obtained from females
(n=43) treated with dienogest at a dose of 2 mg (dieno-
gest group; n=13) for three to five months or leuprolide
acetate (LA) at a dose of 3.75 mg (LA group; n=16)
administered before surgery. Simultaneous sampling of
ovarian endometrioma capsules was performed during
laparoscopic surgery for indications of adnexal masses
consistent with ovarian endometrioma. The stage of
endometriosis in each case was documented according
to the revised American Society of Reproductive Medi-
cine Criteria (r-AFS stage) [34]. The diagnosis of endo-
metriosis was confirmed histologically. Normal
endometrial tissues (n=17) were obtained using biopsies
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patients undergoing hysterectomy for uterine fibroids.
The samples obtained from the ectopic and eutopic
endometrium were immediately frozen in liquid nitrogen
for further RT-PCR analyses, fixed in 10% formaldehyde
and then routinely processed for paraffin embedding for
a histological analysis.OneStep real-time polymerase chain reaction
Total RNA was obtained using the RNeasy Mini kit
(Qiagen, Germantown MD), and 2μg were reverse tran-
scribed with Superscript II RNase H-reverse transcript-
ase (Invitrogen) using random primers according to the
manufacturer’s instructions. Oligonucleotide primers for
TaqMan probes were designed with the use of Primer
Express (version 1.0; Perkin-Elmer Applied Biosystems,
Tokyo, Japan) from the GeneBank database. Human
GAPDH was purchased from Perkin-Elmer Applied Bio-
systems and used as an internal standard. The primers
used in this study are shown in Table 1. The first primer
set, termed PR-B, was designed to amplify sequences
specific for PR-B (upstream of the second AUG transla-
tion initiation site), whereas the second primer set, total
PR, was designed to amplify sequences downstream of
the second AUG translation initiation site. None of these
primer sets corresponded to sequences in any of the
other steroid hormone receptors. The cDNA template
was amplified using quantitative real-time polymerase
chain reaction (qRT-PCR), as previously described [35].
Briefly, the cDNA template was amplified in a 20 μL reac-
tion containing 1 x TaqMan Universal PCR Master Mix
(Perkin-Elmer Applied Biosystems), 200 nM forward and
reverse primers and 100 nM TaqMan probe. The TaqMan
PCR conditions were: 95°C for 15 seconds followed by
60°C for one minute for 45 cycles in each case on OneStep
real-time PCR (Perkin-Elmer Applied Biosystems). The
amplification of the target gene mRNA relative to
GAPDH was compared using the ΔΔCt method. The
abundance of PR-A was calculated by subtracting the











All specimens fixed in 10% paraformaldehyde solution
were embedded in paraffin blocks. The sections were
stained with hematoxylin and eosin for histological evalu-
ation of the tissues. For deection of PR-A, a human PR-A-
specific mouse monoclonal antibody purchased from
Novocastra (NCL-L-PGR-312; Vision BioSystems Inc.,
Norwell, MA) was used [36,37]. For PR-B immunostain-
ing, mouse monoclonal antibody Ab-6 (NeoMarkers, Fre-
mont, CA) was used [36,38]. For ERα and ERβ
immunostaining, rabbit polyclonal antibodies (LS-B1470
and LS-B945, respectively, LifeSpan Biosciences, Seattle,
WA, USA) were used. The antigen-antibody complexes
were identified using the Universal DAKO LSAB2-labeled
streptavidin-biotin peroxidase kit (Lifespan Biosciences).
Statistics
All experiments were performed in triplicate. The statis-
tical calculations were performed using the StatView
statistical software package (SAS Institute, Cary, NC),
and the statistical significance of each difference was
determined using the Kruskal-Wallis and Mann-
Whitney U test or paired t-test as appropriate. A P value
of < 0.05 was considered to be statistically significant.
Results
Patient characteristics
A total of 14 females who did not receive any medical
treatment, 13 females who received dienogest and 16
females who received LA were evaluated in this study
(Table 2). There were no relevant group differences in
age or VAS at baseline. The use of concomitant medica-
tions recorded in patient-maintained diaries, including
analgesic medications for endometriosis, did not differ
relevantly between the groups at baseline.
At baseline, the mean ± SD VAS score was 53.1 ± 29.9
mm in the endometriosis-control group, 46.2 ± 22.6 mm
in the endometriosis-dienogest group and 56.3 ± 41.0
mm in the LA group. Following surgical treatment, the
mean VAS score decreased to 20.6 ± 15.1 mm in the
dienogest group and 21.1 ± 18.0 mm in the LA group,
demonstrating the non-inferiority of dienogest versus
LA as measured by observed VAS score changes. At
baseline, the mean ± SD serum CA125 level was 60.3 ±
34.1 U/ml in the endometriosis-control group, 60.6 ±
35.8 U/ml in the endometiosis-dienogest group and
52.9 ± 42.8 U/ml in the LA group. Following surgical
treatment, the mean serum CA125 level significantly
decreased to 34.8 ± 14.9 U/ml in the dienogest group
and to 34.9 ± 20.8 U/ml in the LA group.
PR isoform expression and PR-B/PR-a ratios in eutopic
and ectopic endometrium
Previous studies have demonstrated that the expression
of repressive PR-A and the apparent downregulation of







Control (n=14) Dienogest 2 mg (n=13) LA 3.75 mg (n=16)
baseline baseline baseline preoperation baseline preoperation
Age (years, mean ± SD 44.2 ± 6.8 34.9 ± 8.1 34.3 ± 5.7 37.5 ± 7.2
Duration of drug administration - - 21.6 ± 11.5 12.6 ± 2.8
Pelvic pain VAS (mm, mean ± SD) 23.8 ± 18.2 53.1 ± 29.9 46.2 ± 22.6a 20.6 ± 15.1b 56.3 ± 41.0ab 21.1 ± 18.0b
CA-125 (U/ml, mean ± SD) 33.1 ± 20.4 60.3 ± 34.1 60.6 ± 35.8 34.8 ± 14.9c 52.9 ± 42.8 34.9 ± 20.8
r-AFS stage (n,%)
I: minimal 10 (58%) 0 (0%) 0 (0%) 0 (0%)
II: mild 3 (18%) 0 (0%) 0 (0%) 2 (13%)
III: moderate 4 (24%) 5 (36%) 8 (62%) 9 (56%)
IV: severe 0 (0%) 9 (64%) 5 (38%) 5 (31%)
LA, leuprolide acetate; VAS, visual analogue scale; r-AFS, revised American Fertility Society.
SD, standard deviation.
A: p <0.01 compared to patients with uterine fibroids, b: p <0.01 compared to endometriosis-control, c: p <0.05 compared to baseline.
Hayashi et al. Journal of Ovarian Research 2012, 5:31 Page 4 of 8
http://www.ovarianresearch.com/content/5/1/31stimulatory PR-B may explain the development of pro-
gesterone resistance in patients with endometriosis
[1,39]. This study investigated whether treatment with
dienogest or leuprolide acetate attenuates the expression




















































Figure 1 PRs expression and PR-B/PR-A ratios in eutopic/ectopic endo
acetate. Total RNA was isolated from eutopic endometrial samples (Eutopi
phase of the menstrual cycle in patients undergoing hysterectomy for uter
obtained from females who did not receive medical treatment (Control, n=
dienogest at a dose of 2 mg (Dienogest, n=13) or leuprolide acetate (LA, n
expression ratio of the PR-B gene was calculated in comparison to the GAP
calculated by subtracting the relative abundance of PR-B from that of total
illustrated as the ratio between the relative expressions of PR-B and PR-A. T
bars indicate the 25–75 percentiles. Significant differences are indicated byThe expression of PR-B (Figure 1A) was significantly
dysregulated in control ectopic endometrial samples
obtained from females who did not receive any treatment
compared with that observed in the eutopic endometrium

























metrium following treatment with dienogest or leuprolide
c, n=17) obtained with biopsies performed during the proliferative
ine fibroids. Total RNA was also isolated from endometriotic samples
14) and endometriotic samples obtained from females treated with
=16). The total RNA was then reverse-transcribed. A: The relative
DH expression. B: The relative expression ratio of the PR-A gene was
PR. C: For each experimental sample, the data are graphically
he center lines indicate the median ratio. The columns and vertical
an asterisk. *p<0.05, **p<0.01.
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gest or LA treatment showed a significantly greater ex-
pression of PR-B compared with that observed in the
control tissues. The expression of PR-A (Figure 1B) was
also significantly decreased in control ectopic endometrial
samples compared with that observed in eutopic endo-
metrium. Although the endometrioma samples obtained
from the patients who received LA treatment showed a
significantly greater expression of PR-A, dienogest treat-
ment did not alter the expression of PR-A. Typical mRNA
expression patterns of the PR isoforms are shown in the
Additional file 1: Figure A, and explained in the Add-
itional file 2. Progesterone resistance may be explained by
the absence of PR-B and the dominant expression of PR-A
[20,21]; therefore, we analyzed the PR-B/PR-A ratio at the
mRNA level (Figure 1C). In the control ectopic endomet-
rial samples, the PR-B/PR-A ratio was significantly
decreased compared with that observed in eutopic endo-
metrium. Interestingly, dienogest treatment improved the
PR-B/PR-A ratio; however, there were no significant differ-
ences in endometrioma after LA treatment.
ER isoform expression and ERβ/ERα ratios in eutopic and
ectopic endometrium
This study investigated whether treatment with dieno-
gest or leuprolide acetate attenuates the expression of
ER isoforms in ectopic endometrium.
The expression of ERα (Figure 2A) was significantly dys-




















































Figure 2 ERs expression and ERβ/ERα ratios in eutopic/ectopic endom
Total RNA was isolated from eutopic endometrial samples (Eutopic, n=17)
menstrual cycle in patients undergoing hysterectomy for uterine fibroids. T
females who did not receive medical treatment (Control, n=14) and endom
dose of 2 mg (Dienogest, n=13) or leuprolide acetate (LA, n=16). The total
the ERα gene was calculated in comparison to the GAPDH expression. B: T
comparison to the GAPDH expression. C: For each experimental sample, th
expressions of ERβ and ERα. The center lines indicate the median ratio. The
differences are indicated by an asterisk. *p<0.05, **p<0.01.obtained from females who did not receive any treatment
compared with that observed in the eutopic endometrium
of patients with fibroids. In addition, the endometrioma
samples obtained from the patients who received dienogest
or LA treatment showed a significantly lower expression of
ERα compared with that observed in eutopic endomet-
rium. The expression of ERβ (Figure 2B) was also signifi-
cantly elevated in the control ectopic endometrial samples
compared with that observed in eutopic endometrium.
Dienogest, but not LA, treatment altered the expression of
ERβ. Typical mRNA expression pattern of the ER isoforms
are shown in the Additional file 1: Figure B, and explained
in Additional file 2. A number of investigators have
reported markedly elevated levels of ERβ and lower levels
of ERα in human endometriotic tissues compared with
that observed in eutopic endometrial tissues and cells
[16,22,23]. Therefore, we also analyzed the ERβ/ERα ratio
at the mRNA level (Figure 2C). In the control ectopic
endometrial samples, the ERβ/ERα ratio was significantly
increased compared with that observed in eutopic endo-
metrium. Interestingly, dienogest treatment significantly
improved the ERβ/ERα ratio; however, there were no sig-
nificant differences in endometrioma after LA treatment.
Expression of PR and ER isoform proteins in the eutopic
and ectopic endometriotic samples
An immunohistochemical analysis revealed that PR-B
immunoreactivity was strongly localized to the glandular
























etrium following treatment with dienogest or leuprolide acetate.
obtained with biopsies performed during the proliferative phase of the
otal RNA was also isolated from endometriotic samples obtained from
etriotic samples obtained from females treated with dienogest at a
RNA was then reverse-transcribed. A: The relative expression ratio of
he relative expression ratio of the ERβ gene was calculated in
e data are graphically illustrated as the ratio between the relative
columns and vertical bars indicate the 25–75 percentiles. Significant
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faintly localized to the glandular epithelium in the control
ectopic endometrium (Figure 3F). In contrast, PR-A
immunoreactivity appeared faintly in both the eutopic
endometrial samples (Figure 3A) and the control ectopic
endometrium (Figure 3B). After the patients were treated
with dienogest or LA, immunostaining of PR-B increased
in the ectopic endometrial epithelium (Figure 3G and H).
ERα was strongly localized to the glandular epithelium
and stromal cells in the eutopic endometrium (Figure 3I)
and faintly localized in the control ectopic endometrium
(Figure 3J). Dienogest and LA treatment had no effect on
the ERα expression (Figure 3K and L). ERβ immunoreac-
tivity appeared faintly in the eutopic endometrial samples
(Figure 3M). In contrast, ERβ was strongly localized to the
epithelium and stromal cells in the ectopic endometrium
(Figure 3N). Although dienogest treatment decreased the


















Figure 3 Typical example of PR and ER isoform expression in patient
PR-A (A, B, S, D) and PR-B (E, F, G, H) antibodies. ERα and ERβ were detect
endometrium (A, E, I, M) in the proliferative phase was obtained from fem
endometrium was obtained from endometrioma of the control females (B
(D, H, L, P). Scale bar: 25 m.treatment seemed to have no effect on the ERβ expression
(Figure 3P). No immunostaining was found in eutopic or
ectopic endometrium when the primary antibodies were
omitted (data not shown).
Discussion
The current study demonstrated statistically significant
decreases in both PR–B and PR-A messenger RNA and
proteins in ectopic endometrium derived from females with
endometrioma who did not receive any medical treatment
(Figure 1A, 1B, 3B, and 3F). Furthermore, the relative
expressions of PR-B and PR-A were significantly lower in
ectopic endometrium (Figure 1C). According to Attia et al.
[20], the resistance of endometriotic tissue to progesterone,
evident in both laboratory and clinical observations, can be
explained by the absence of PR-B transcripts and proteins
and the presence of PR-A in ectopic lesions. Similar find-





s with ovarian endometriosis. PR-A and PR-B were detected using
ed using ERα (I, J, K, L) and ERβ (M, N, O, P) antibodies. The eutopic
ales undergoing hysterectomy for uterine fibroids. The ectopic
, F, J, N), dienogest-treated females (C, G, K, O) and LA-treated females
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ent investigators suggested that alterations in the relative
expressions of PR-A and PR-B in endometrial cells may also
play a pivotal role in the pathogenesis of endometriosis. A
decreased PR-B/PR-A ratio has been demonstrated in ec-
topic tissue [5,10], and our findings are consistent with the
results of these studies.
Several investigators have reported markedly higher
levels of ERβ and lower levels of ERα in human endome-
triotic tissues and primary stromal cells compared with
that observed in eutopic endometrial tissues and cells
[22,40]. Recently, Bulun [41] reported that the levels of the
nuclear receptors ERα, ERβ and PR are quite different in
endometriotic tissue and endometrium. The high ERβ/
ERα ratiosin endometriotic stromal cells in turn lead to
increased ERβ binding to the PR promoter and mediate
downregulation of the expression of PR [21]. ERβ acts as a
suppressor of ERα in both endometrial and endometriotic
stromal cells by binding to regulatory elements of specific
promoters of the ERα and PR genes [42]. Therefore, ERα
deficiency in endometriotic patients may be responsible
for the failure of E2 to induce the PR expression, thus
contributing to secondary PR deficiency and progesterone
resistance in females with endometriosis. Although strik-
ingly high quantities of E2 produced via local aromatase
activity are observed in endometriotic tissue [43,44], the
E2-dependent induction of PR is strongly inhibited [20].
Findings consistent with these studies were observed in
the current study, which demonstrated statistically
significant higher levels of ERβ and lower levels of ERα in
ectopic endometrium derived from females with endome-
trioma (Figure 2 and Figure 3).
The endometrioma samples obtained from the patients
who received dienogest or LA treatment showed a
significantly higher expression of PR-B compared with
that observed in the control endometrioma samples
(Figure 1A and Figure 3). Although LA treatment
increased the PR-A expression in the endometrioma
samples, dienogest treatment did not alter the expres-
sion of PR-A (Figure 1B). Consequently, dienogest treat-
ment improved the PR-B/PR-A ratio; however, there
were no significant differences in endometrioma after
LA treatment (Figure 1C). Progesterone has recently
been shown to reverse E2-stimulated increases in the
ERβ mRNA and protein expression in cultured hippo-
campal slices [45]. Our current study demonstrates that
dienogest treatment alters the expression of ERβ
(Figure 2B and Figure 3) and significantly decreases the
ERβ/ERα ratio in endometrioma (Figure 2C). A recent
report demonstrated that the promoter region of PR-B,
but not PR-A, is hypermethylated in patients with endo-
metriosis [21]. Although further studies are needed to
clarify whether medical treatments might be associated
with the methylation status of the PR-B promoter and toexplore the mechanisms underlying the ERβ downregu-
lation induced by dienogest, a decreased ERβ/ERα ratio
in the endometriotic tissues of patients treated with die-
nogest may be responsible for the observed improve-
ments in the PR expressions.
Conclusions
We demonstrated that dienogest improves progesterone
resistance in endometrial tissue. This finding enhances
understanding of the anti-endometriotic effects of dieno-
gest. It is possible that PR-B deficiency is only the tip of
the iceberg with regard to the pathogenesis of endomet-
riosis and that numerous other molecular aberrations
may also contribute to the development of resistance to
hormone treatments in females with endometriosis. Al-
though our findings may explain at least part of the
mechanisms underlying the clinical improvements
observed in endometriotic patients using dienogest, the
normalization of the PR expression profile observed in
this study suggests that dienogest may be an effective
and long-term treatment for endometriosis.
Additional files
Additional file 1: Typical mRNA expression patterns of the PR and
ER isoforms. A: A representative agarose gel showing amplicons of PR-B
(upper panel), total-PR (middle panel), and β-actin (lower panel). B: A
representative agarose gel showing amplicons of ERα (upper panel), ERβ
(middle panel), and β-actin (lower panel).
Additional file 2: Supplemental Results.
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